Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HUC3-637 in primary open angle glaucoma or ocular hypertension
NCT07335211Phase 3Recruiting
- Sponsor
- Huons
- Start
- Jan 2026
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dorzolamide + timolol in primary open-angle glaucoma (POAG), ocular hypertension, sponsored by Huons. Started Jan 2026; status: recruiting.
02
Drugs
dorzolamide + timolol
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT07335211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07335211.